Drugs / ONM-501
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06022029 | Oct 2023 → Apr 2026 overdue | cervical cancer, diffuse large B-cell lymphoma, follicular lymphoma, head and neck squamous cell carcinoma +7 | OncoNano Medicine, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONM-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06022029 ↗ |
| Route | Other | “Intratumoral injection” NCT06022029 ↗ |